NURO - NeuroMetrix, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.7700
-0.1000 (-2.05%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.8700
Open4.8300
Bid4.7700 x 1100
Ask4.8200 x 1000
Day's Range4.6000 - 4.9399
52 Week Range2.5000 - 13.8000
Volume66,986
Avg. Volume91,914
Market Cap4.5M
Beta (3Y Monthly)0.51
PE Ratio (TTM)N/A
EPS (TTM)-6.5010
Earnings DateOct 18, 2017 - Oct 23, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2007-03-28
1y Target Est50.00
  • NuVasive (NUVA) Hits 52-Week High, Can the Run Continue?
    Zacks

    NuVasive (NUVA) Hits 52-Week High, Can the Run Continue?

    NuVasive (NUVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • GlobeNewswire

    NeuroMetrix Announces One-for-Ten Reverse Split

    NeuroMetrix, Inc. (NURO) today announced the effectiveness of a one-for-ten reverse split of its common stock. The shares underlying the Company's outstanding options and warrants will also be adjusted accordingly. The reverse stock split is intended to increase the per share trading price of the Company's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.

  • NeuroMetrix (NASDAQ:NURO) Will Have To Spend Its Cash Wisely
    Simply Wall St.

    NeuroMetrix (NASDAQ:NURO) Will Have To Spend Its Cash Wisely

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • Thomson Reuters StreetEvents

    Edited Transcript of NURO earnings conference call or presentation 17-Oct-19 12:00pm GMT

    Q3 2019 NeuroMetrix Inc Earnings Call

  • Benzinga

    The Daily Biotech Pulse: Intuitive Surgical Earnings, Paratek Pulls Out European Application For Antibiotic, Amgen's Evenity In Europe

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 17) Applied Therapeutics Inc (NASDAQ: APLT ) Arrowhead ...

  • GlobeNewswire

    NeuroMetrix Reports Q3 2019 Financial Results

    WOBURN, Mass., Oct. 17, 2019 -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2019. The Company.

  • GlobeNewswire

    NeuroMetrix Announces Updates to Quell 2.0 Commercial Strategy

    NeuroMetrix, Inc. (NURO), a health technology company that develops and commercializes products for the chronic pain and diabetes markets, today announced important updates to its Quell® 2.0 commercial strategy.  This novel wearable device for the symptomatic relief of chronic pain is central to the Company’s vision of helping people reclaim their lives from chronic pain through neuroscience and technology. The Company is shifting to an exclusively direct-to-consumer model delivered via the QuellRelief.com website, that will allow it to offer the innovative Quell 2.0 system at accessible price points.  This streamlined distribution model will allow more people with chronic pain to benefit from the advanced Quell pain relief technology.  The new approach will also open the door for more people to take advantage of electrode savings through a subscription service.

  • GlobeNewswire

    NeuroMetrix, Inc. Announces Date for Third Quarter 2019 Financial Results Conference Call

    NeuroMetrix, Inc. (NURO) announced today that it plans to issue its 2019 third quarter financial results before the opening of the market on Thursday, October 17, 2019. The Company will host a conference call at 8:00 a.m., Eastern Time on October 17, 2019 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 3999665.

  • Thomson Reuters StreetEvents

    Edited Transcript of NURO earnings conference call or presentation 18-Jul-19 12:00pm GMT

    Q2 2019 NeuroMetrix Inc Earnings Call

  • GlobeNewswire

    NeuroMetrix Reports Q2 2019 Financial Results

    WALTHAM, Mass., July 18, 2019 -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended June 30, 2019. The Company develops.

  • ACCESSWIRE

    NeuroMetrix, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 18, 2019 / NeuroMetrix, Inc. (NASDAQ: NURO ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 18, 2019 at 8:00 AM Eastern ...

  • Insulet (PODD) Soars to 52-Week High, Time to Cash Out?
    Zacks

    Insulet (PODD) Soars to 52-Week High, Time to Cash Out?

    Insulet (PODD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • GlobeNewswire

    NeuroMetrix, Inc. Announces Date for Second Quarter 2019 Financial Results Conference Call

    NeuroMetrix, Inc. (NURO) announced today that it plans to issue its 2019 second quarter financial results before the opening of the market on Thursday, July 18, 2019. The Company will host a conference call at 8:00 a.m., Eastern Time on July 18, 2019 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 7357689.

  • Analysts Estimate NeuroMetrix (NURO) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate NeuroMetrix (NURO) to Report a Decline in Earnings: What to Look Out for

    NeuroMetrix (NURO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Benzinga

    The Daily Biotech Pulse: Chiasma To Join R3K Index, EU Rejects Amgen's Osteoporosis Drug Application, Karuna IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on June 27) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) (received ...

  • GlobeNewswire

    NeuroMetrix Provides Strategic Update

    NeuroMetrix, Inc. (NURO), a health technology company addressing chronic health conditions including chronic pain, sleep disorders and diabetes, today reported on its strategy of optimizing its commercial products while reducing operating costs and preserving cash. The Company is focused on supporting its DPNCheck® product line, managing its existing Quell® business while evaluating alternative therapeutic applications for the core technology, maintaining its strategic collaboration with GlaxoSmithKline, and attempting to negotiate a settlement of the previously disclosed and ongoing Federal Trade Commission (FTC) investigation which is centered on Quell advertising. In its efforts to preserve cash, the Company has implemented a reduction in force affecting 11 employees, all of whom have ceased employment with the Company.

  • GlobeNewswire

    NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable Technology

    NeuroMetrix, Inc. (NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,293,159 titled “Measuring the ‘on-skin’ time of a Transcutaneous Electrical Nerve Stimulator (TENS) device in order to minimize skin irritation due to excessive uninterrupted wearing of the same.” The patent covers novel methods to help Quell® users safely obtain wearable TENS therapy over extended time periods. "We are pleased to have received this latest patent for Quell technology," said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. Quell is drug-free and has been cleared by the FDA for relief and management of chronic pain without a prescription.

  • Thomson Reuters StreetEvents

    Edited Transcript of NURO earnings conference call or presentation 25-Apr-19 12:00pm GMT

    Q1 2019 NeuroMetrix Inc Earnings Call

  • If You Had Bought NeuroMetrix (NASDAQ:NURO) Stock Five Years Ago, You'd Be Sitting On A 99% Loss, Today
    Simply Wall St.

    If You Had Bought NeuroMetrix (NASDAQ:NURO) Stock Five Years Ago, You'd Be Sitting On A 99% Loss, Today

    We're definitely into long term investing, but some companies are simply bad investments over any time frame. We don't wish catastrophic capital loss on anyone. For example, we sympathize with anyone who was caught holding Ne...

  • GlobeNewswire

    NeuroMetrix Reports Q1 2019 Financial Results

    WALTHAM, Mass., April 25, 2019 -- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter ended March 31, 2019. The Company develops.

  • GlobeNewswire

    NeuroMetrix, Inc. Announces Date for First Quarter 2019 Financial Results Conference Call

    NeuroMetrix, Inc. (NURO) announced today that it plans to issue its 2019 first quarter financial results before the opening of the market on Thursday, April 25, 2019. The Company will host a conference call at 8:00 a.m., Eastern Time on April 25, 2019 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 3589503.

  • Earnings Preview: NeuroMetrix (NURO) Q1 Earnings Expected to Decline
    Zacks

    Earnings Preview: NeuroMetrix (NURO) Q1 Earnings Expected to Decline

    NeuroMetrix (NURO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.